+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gout Medications Market - Global Forecast 2026-2032- Product Image
Gout Medications Market - Global Forecast 2026-2032- Product Image
Sale

Gout Medications Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6128609
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gout Medications Market is projected to reach USD 3.12 Billion in 2026. It is expected to continue growing at a CAGR of 6.31%, reaching USD 4.51 Billion by 2032.

Gout Medications: Executive Summary and Strategic Context

Gout medications address acute flares, urate-lowering needs, and prevention of recurrent attacks. The therapeutic landscape includes anti-inflammatory treatments for symptom control and medicines that reduce serum urate over time. Clinical decision-making depends on disease severity, comorbidities, renal and hepatic function, treatment tolerability, adherence, and access to diagnosis and follow-up care.

Treatment Is Shifting Toward Long-Term, Guideline-Based Disease Control

Management is increasingly moving beyond episodic relief toward sustained urate control, treat-to-target monitoring, and prevention of joint damage and recurrent flares. Greater recognition of gout as a chronic inflammatory disease is supporting earlier initiation or optimization of urate-lowering therapy when clinically appropriate. At the same time, safety considerations, drug interactions, renal impairment, cardiovascular risk, and patient adherence continue to shape therapeutic selection.

Artificial Intelligence Supports More Personalized Gout Management

Artificial intelligence can contribute to gout care through risk stratification, imaging interpretation, identification of patients likely to experience flares, and analysis of longitudinal laboratory and treatment data. Decision-support systems may help clinicians recognize undertreatment, anticipate adherence barriers, and tailor monitoring intervals. However, clinical validation, transparent algorithms, data privacy, interoperability, and human oversight remain essential before AI-derived recommendations are used routinely.

Regional Differences Reflect Diagnosis, Access, and Chronic-Care Capacity

North America generally benefits from established specialty care and broad availability of diagnostic and laboratory services, while affordability and adherence remain important considerations. Europe combines mature clinical systems with variation in national guidelines, reimbursement, and access across countries. Asia-Pacific presents substantial diversity, including rising diagnosis in urban settings alongside gaps in specialist coverage and continuity of care. Latin America continues to face uneven access to testing and chronic treatment. The Middle East is shaped by expanding healthcare infrastructure, metabolic risk factors, and differences in insurance coverage. Africa has considerable unmet needs related to diagnostic capacity, medicine availability, and long-term follow-up, with care pathways varying widely across countries.

Economic and Political Groupings Reveal Different Care Priorities

ASEAN markets require approaches that account for varied healthcare financing, urbanization, supply chains, and diagnostic capacity. BRICS members span advanced and emerging systems, creating divergent needs for affordable medicines, primary-care training, and reliable laboratory monitoring. The European Union emphasizes harmonized evidence standards while retaining national differences in reimbursement and clinical implementation. G7 countries typically focus on guideline adherence, safety surveillance, multimorbidity, and health-system efficiency. GCC countries are prioritizing chronic-disease management amid differing coverage models and high metabolic-risk burdens. NATO members represent diverse health systems, but continuity of care, procurement resilience, and preparedness for supply disruptions are shared concerns.

Country-Level Priorities Range from Access Expansion to Treatment Optimization

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States have relatively developed clinical and regulatory infrastructures, with priorities including earlier diagnosis, adherence, renal-risk management, and consistent implementation of treat-to-target care. Brazil, China, India, Mexico, and Russia face more varied access conditions and regional disparities, increasing the importance of affordable treatment pathways, primary-care education, laboratory availability, and dependable medicine supply. Across all listed countries, integrating gout management with care for obesity, kidney disease, hypertension, diabetes, and cardiovascular conditions can improve clinical coordination.

Industry Leaders Should Prioritize Evidence, Access, and Patient Persistence

Leaders should align product development and clinical education with contemporary guideline-based care, clearly differentiate acute treatment from long-term urate control, and generate evidence in patients with common comorbidities. Strengthening patient-support programs, adherence tools, renal- and cardiovascular-safety communication, and clinician training can improve persistence. Organizations should also invest in resilient distribution, responsible use of real-world evidence, validated digital monitoring, and AI governance that protects privacy while demonstrating measurable clinical value.

Methodology: Evidence-Based Synthesis of the Gout Medication Landscape

This executive summary synthesizes established clinical and health-system considerations relevant to gout medications, including treatment roles, patient-management needs, access conditions, and technology applications. Insights are organized across the required regions, economic and political groups, and countries. The analysis intentionally excludes market estimates, sizing, shares, forecasts, and company-specific claims, and treats the supplied market reference solely as a topic definition.

Conclusion: Better Outcomes Depend on Continuous, Integrated Gout Care

The gout medication landscape is being shaped by a shift from flare-by-flare treatment toward sustained disease control, personalized monitoring, and integration with broader chronic-care services. Regional and country differences in diagnosis, affordability, reimbursement, and clinical capacity will determine how consistently these approaches are applied. Progress will depend on clinically validated innovation, dependable access, patient engagement, and careful use of digital and AI-enabled tools.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Gout Medications Market, by Drug Class
7.1. Introduction
7.2. Xanthine Oxidase Inhibitors
7.2.1. Purine-analog XOI
7.2.2. Non-purine XOI
7.3. Colchicine
7.4. Nonsteroidal Anti-Inflammatory Drugs
7.4.1. Non-selective NSAIDs
7.4.2. COX-2 selective NSAIDs
7.5. Corticosteroids
7.6. Uricosurics
7.6.1. Non-selective Inhibitors
7.6.2. Selective URAT1 Inhibitors
7.7. Interleukin-1 Inhibitors
7.7.1. L-1ß Monoclonal Antibody
7.7.2. IL-1 Receptor Antagonist
7.7.3. IL-1 Trap
8. Gout Medications Market, by Route Of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
9. Gout Medications Market, by Dosage Form
9.1. Introduction
9.2. Capsules
9.3. Injectables
9.4. Oral Solutions
9.5. Tablets
10. Gout Medications Market, by Indication
10.1. Introduction
10.2. Acute Gout Treatment
10.3. Chronic Gout Management
11. Gout Medications Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Gout Medications Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Specialty Clinics
12.4. Home Care
12.5. Hospitals
13. Gout Medications Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. Europe
13.4. North America
13.5. Latin America
13.6. Middle East
13.7. Africa
14. Gout Medications Market, by Group
14.1. Introduction
14.2. NATO
14.3. G7
14.4. BRICS
14.5. European Union
14.6. GCC
14.7. ASEAN
15. Gout Medications Market, by Country
15.1. Introduction
15.2. United States
15.3. China
15.4. India
15.5. Germany
15.6. Japan
15.7. United Kingdom
15.8. Canada
15.9. Brazil
15.10. France
15.11. Mexico
15.12. Italy
15.13. Spain
15.14. Russia
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen Inc.
17.2. Novartis AG
17.3. ANI Pharmaceuticals, Inc.
17.4. A.Menarini Industrie Farmaceutiche Riunite S.r.l.
17.5. Eisai Co., Ltd.
17.6. Teva Pharmaceutical Industries Ltd
17.7. Aurobindo Pharma Limited
17.8. Viatris, Inc.
17.9. Hikma Pharmaceuticals PLC
17.10. Alembic Pharmaceuticals Ltd.
17.11. Alkem Laboratories Limited
17.12. Amneal Pharmaceuticals, Inc.
17.13. Camber Pharmaceuticals, Inc.
17.14. Dr. Reddy’s Laboratories, Ltd.
17.15. Gensco Pharma LLC
17.16. Intas Pharmaceuticals Ltd.
17.17. Lupin Limited
17.18. Pfizer Inc.
17.19. Rising Pharmaceuticals Holdings, Inc.
17.20. Scilex Holding Company
17.21. Swedish Orphan Biovitrum AB
17.22. Takeda Pharmaceutical Company Limited
17.23. Teijin Pharma Limited
17.24. XORTX Therapeutics Inc.
17.25. Zydus Lifesciences Limited
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Gout Medications Market, Years Considered for the Study
FIGURE 2. Global Gout Medications Market, Research Design
FIGURE 3. Global Gout Medications Market, Research Framework
FIGURE 4. Global Gout Medications Market, Data Triangulation
FIGURE 5. Global Gout Medications Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Gout Medications Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Gout Medications Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Gout Medications Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 9. Global Gout Medications Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Gout Medications Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 11. Global Gout Medications Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Gout Medications Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 13. Global Gout Medications Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Gout Medications Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global Gout Medications Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Gout Medications Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Gout Medications Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Gout Medications Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Gout Medications Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Gout Medications Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Gout Medications Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Gout Medications Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Gout Medications Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Gout Medications Market Segmentation & Coverage
TABLE 2. Global Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 3. Global Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Xanthine Oxidase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Xanthine Oxidase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Xanthine Oxidase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Purine-analog XOI Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Purine-analog XOI Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Purine-analog XOI Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Non-purine XOI Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Non-purine XOI Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Non-purine XOI Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Colchicine Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Colchicine Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Colchicine Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Nonsteroidal Anti-Inflammatory Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Non-selective NSAIDs Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Non-selective NSAIDs Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Non-selective NSAIDs Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global COX-2 selective NSAIDs Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global COX-2 selective NSAIDs Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global COX-2 selective NSAIDs Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Corticosteroids Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Corticosteroids Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Corticosteroids Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Uricosurics Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Uricosurics Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Uricosurics Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Non-selective Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Non-selective Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Non-selective Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Selective URAT1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Selective URAT1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Selective URAT1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Interleukin-1 Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Interleukin-1 Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Interleukin-1 Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global L-1ß Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global L-1ß Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global L-1ß Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global IL-1 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global IL-1 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global IL-1 Receptor Antagonist Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global IL-1 Trap Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global IL-1 Trap Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global IL-1 Trap Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 50. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 60. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Injectables Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Injectables Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Injectables Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Oral Solutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Oral Solutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Oral Solutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 73. Global Acute Gout Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Acute Gout Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Acute Gout Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Chronic Gout Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Chronic Gout Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Chronic Gout Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 90. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Gout Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Gout Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 114. Europe Gout Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Europe Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 116. Europe Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 117. Europe Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 118. Europe Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 119. Europe Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 120. Europe Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 121. Europe Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 122. Europe Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. Europe Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 124. Europe Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. North America Gout Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. North America Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 127. North America Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 128. North America Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 129. North America Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 130. North America Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 131. North America Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 132. North America Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 133. North America Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 134. North America Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 135. North America Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 136. Latin America Gout Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 137. Latin America Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 138. Latin America Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 139. Latin America Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 140. Latin America Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 141. Latin America Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 142. Latin America Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 143. Latin America Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 144. Latin America Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 145. Latin America Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 146. Latin America Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 147. Middle East Gout Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 148. Middle East Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 149. Middle East Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 150. Middle East Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 151. Middle East Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 152. Middle East Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 153. Middle East Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 154. Middle East Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 155. Middle East Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 156. Middle East Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 157. Middle East Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 158. Africa Gout Medications Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Africa Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 160. Africa Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 161. Africa Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 162. Africa Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 163. Africa Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 164. Africa Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 165. Africa Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 166. Africa Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 167. Africa Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 168. Africa Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 169. Global Gout Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 170. NATO Gout Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. NATO Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 172. NATO Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 173. NATO Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 174. NATO Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 175. NATO Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 176. NATO Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 177. NATO Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 178. NATO Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. NATO Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. NATO Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. G7 Gout Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. G7 Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 183. G7 Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 184. G7 Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 185. G7 Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 186. G7 Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 187. G7 Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 188. G7 Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 189. G7 Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 190. G7 Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 191. G7 Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. BRICS Gout Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 193. BRICS Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 194. BRICS Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 195. BRICS Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 196. BRICS Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 197. BRICS Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 198. BRICS Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. BRICS Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 200. BRICS Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 201. BRICS Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 202. BRICS Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 203. European Union Gout Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. European Union Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 205. European Union Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 206. European Union Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 207. European Union Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 208. European Union Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 209. European Union Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 210. European Union Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 211. European Union Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 212. European Union Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 213. European Union Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 214. GCC Gout Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 215. GCC Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 216. GCC Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 217. GCC Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 218. GCC Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 219. GCC Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 220. GCC Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 221. GCC Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 222. GCC Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 223. GCC Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 224. GCC Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 225. ASEAN Gout Medications Market Size, by Group, 2017-2032 (USD Million)
TABLE 226. ASEAN Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 227. ASEAN Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 228. ASEAN Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 229. ASEAN Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 230. ASEAN Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 231. ASEAN Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 232. ASEAN Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 233. ASEAN Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 234. ASEAN Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 235. ASEAN Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Global Gout Medications Market Size, by Country, 2017-2032 (USD Million)
TABLE 237. United States Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 238. United States Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 239. United States Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 240. United States Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 241. United States Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 242. United States Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 243. United States Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 244. United States Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 245. United States Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 246. United States Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 247. United States Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. China Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 249. China Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 250. China Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 251. China Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 252. China Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 253. China Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 254. China Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 255. China Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 256. China Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 257. China Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 258. China Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. India Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 260. India Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 261. India Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 262. India Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 263. India Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 264. India Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 265. India Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 266. India Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 267. India Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 268. India Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. India Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 270. Germany Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 271. Germany Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 272. Germany Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 273. Germany Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 274. Germany Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 275. Germany Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 276. Germany Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 277. Germany Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 278. Germany Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 279. Germany Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 280. Germany Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 281. Japan Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 282. Japan Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 283. Japan Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 284. Japan Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 285. Japan Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 286. Japan Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 287. Japan Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 288. Japan Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 289. Japan Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 290. Japan Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 291. Japan Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. United Kingdom Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 293. United Kingdom Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 294. United Kingdom Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 295. United Kingdom Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 296. United Kingdom Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 297. United Kingdom Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 298. United Kingdom Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 299. United Kingdom Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 300. United Kingdom Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 301. United Kingdom Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 302. United Kingdom Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 303. Canada Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 304. Canada Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 305. Canada Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 306. Canada Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 307. Canada Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 308. Canada Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 309. Canada Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 310. Canada Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 311. Canada Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 312. Canada Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 313. Canada Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. Brazil Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 315. Brazil Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 316. Brazil Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 317. Brazil Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 318. Brazil Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 319. Brazil Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 320. Brazil Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 321. Brazil Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 322. Brazil Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 323. Brazil Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 324. Brazil Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 325. France Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 326. France Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 327. France Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 328. France Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 329. France Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 330. France Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 331. France Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 332. France Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 333. France Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 334. France Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 335. France Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 336. Mexico Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 337. Mexico Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 338. Mexico Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 339. Mexico Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 340. Mexico Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 341. Mexico Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 342. Mexico Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 343. Mexico Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 344. Mexico Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 345. Mexico Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 346. Mexico Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 347. Italy Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 348. Italy Gout Medications Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 349. Italy Gout Medications Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 350. Italy Gout Medications Market Size, by Nonsteroidal Anti-Inflammatory Drugs, 2017-2032 (USD Million)
TABLE 351. Italy Gout Medications Market Size, by Uricosurics, 2017-2032 (USD Million)
TABLE 352. Italy Gout Medications Market Size, by Interleukin-1 Inhibitors, 2017-2032 (USD Million)
TABLE 353. Italy Gout Medications Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 354. Italy Gout Medications Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 355. Italy Gout Medications Market Size, by Indication, 2017-2032 (USD Million)
TABLE 356. Italy Gout Medications Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 357. Italy Gout Medications Market Size, by End User, 2017-2032 (USD Million)
TABLE 358. Spain Gout Medications Market Size, 2017-2032 (USD Million)
TABLE 359. Spain Gout Medications Market Size, by Drug Class, 2017-2

Companies Mentioned

  • Amgen Inc.
  • Novartis AG
  • ANI Pharmaceuticals, Inc.
  • A.Menarini Industrie Farmaceutiche Riunite S.r.l.
  • Eisai Co., Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Aurobindo Pharma Limited
  • Viatris, Inc.
  • Hikma Pharmaceuticals PLC
  • Alembic Pharmaceuticals Ltd.
  • Alkem Laboratories Limited
  • Amneal Pharmaceuticals, Inc.
  • Camber Pharmaceuticals, Inc.
  • Dr. Reddy’s Laboratories, Ltd.
  • Gensco Pharma LLC
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Pfizer Inc.
  • Rising Pharmaceuticals Holdings, Inc.
  • Scilex Holding Company
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • XORTX Therapeutics Inc.
  • Zydus Lifesciences Limited

Related Topics

Related Reports

Gout Therapeutics Market - Global Forecast 2026-2032 - Product Image

Gout Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Drugs for the Treatment of Refractory Gout Market - Global Forecast 2026-2032 - Product Image

Drugs for the Treatment of Refractory Gout Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Gout Therapeutics Market Report 2026 - Product Image

Gout Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Gout Disease Treatment Market - Global Strategic Business Report - Product Image

Gout Disease Treatment Market - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Chronic Gout - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Chronic Gout - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.